Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function

Journal of Clinical Pharmacology

Volumn 37, Issue 4, 1997, Pages 285-290

  Berenson, James R ^a,b,e   Rosen, Lee ^a,b   Vescio, Robert ^a,b   Lau, Henry S ^d   Woo, Margie ^a   Sioufi, Antoine ^c   Kowalski, M Ortu ^d   Knight, Robert D ^d   Seaman, John J ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Depts Clin Devmt B   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG URINE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PHARMACOKINETICS;

EID: 0030933047     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04304.x     Document Type: Article

References (11)

1. Fitton A, McTavish D: Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41:289-318.
2. Fleisch H: Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In, Brunner KW, Fleisch H, Senn H (eds.): Bisphosphonates and Tumor Osteolysis. New York: Springer-Verlag, 1989; 116:1-28.
3. Passeri M, Baroni MC, Pedrazzoni G, Pioli G, Barbagallo M, Costi D, et al: Intermittent treatment with intravenous 4-amino-1-hydroxylide butyliedene-1, bisphosphonate (AHuBP) in the therapy of post menopausal osteoporosis. Bone Mineral 1991; 15:237-248.
4. Daley-Yates PT, Dodwell DJ, Pongchaidecham A, Coleman RE, Howell A: The clearance of bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991; 49:433-435.
5. Redalieu E, Coleman JM, Chan K, Seaman J, Degen PH, Flesch G, et al: Urinary excretion of aminohydroxypropylidene bisphosphonate in cancer patients after single intravenous infusion. J Pharm Sci 1993; 82:665-667.
6. Cheung WK, Brunner L, Schoenfeld S, Knight R, Seaman J, Brox A, et al: Pharmacokinetics of pamidronate disodium in cancer patients after a single intravenous infusion of 30-, 60-or 90-mg dose over 4 or 24 hours. Am J Therapeut 1994; 1:228-235.
7. Leyvraz S, Hess U, Flesch G, Baer J, Hauffe S, Ford J, et al: Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 1992; 84:788-792.
8. Body JJ, Dumon JC, Ford J, Flesch G: Pharmacokinetics of pamidronate in patients with tumor-induced osteolysis. Bone Mineral 1994; 25;(suppl):S70.
9. Flesch G, Hauffe SA: Determination of the bisphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection. J Chromatogr 1989; 48:446-451.
10. Berenson JR, Lichtenstein A, Porter L, Dimopoulos M, Bordoni R, George S, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 338:488-493.
11. Wingen F, Schmähl D: Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1, 1-diphosphonic acid in mammals. Drug Res 1987; 37:1037-1042.